Obtain prior authorization showing indication‑specific medical necessity

Prior authorization is required and must document that the member meets the indication‑specific criteria in the policy (e.g., prior biologic/targeted‑synthetic use OR specified step and biomarker/response criteria) and that the prescriber is an appropriate specialist. For biologic‑ or targeted‑synthetic‑naive persons, document a negative TB test (PPD or IGRA) within 6 months prior to initiating therapy.

• Medication must be prescribed by or in consultation with one of the listed specialties (see prescriber specialties).
• Examples of indication‑specific evidence: inadequate response to methotrexate for RA, inadequate response to ≥2 NSAIDs for axial SpA, or trial of antibiotics for HS as specified in the policy.

Use the policy‑specified HCPCS/CPT codes when submitting PA and claims

Bill injectable adalimumab to the HCPCS/CPT codes identified by the payer. Common codes referenced include J0135 (injection, adalimumab, 20 mg) and product‑specific Q‑codes for biosimilars (e.g., Q5131). Include supporting lab/procedure codes when relevant (e.g., TB testing, CRP, imaging).

• J0135 is listed for adalimumab 20 mg.
• Q‑codes (e.g., Q5131 for adalimumab‑aacf/idacio) are noted for biosimilars; verify payer‑specific coding/coverage before billing.

Request PA for specific adalimumab product and cite applicable labeling

Prior authorization is required for adalimumab products (J0135 and biosimilar Q‑codes) when the member meets the policy selection criteria; ensure the request identifies the exact product/formulation and aligns with the labeled indication or biosimilar labeling exceptions.

• When requesting coverage for a biosimilar, note any indication omissions in the biosimilar labeling (e.g., some biosimilars omit pediatric HS or UC).
• Include product name or HCPCS/Q‑code on the PA request to match payer billing requirements.

Provide HS diagnosis and prior‑therapy documentation for PA

For hidradenitis suppurativa, prior authorization should include the diagnosis and documentation of prior inadequate response or intolerance to conventional therapies consistent with the PIONEER trial populations (e.g., failure of an oral antibiotic regimen for at least 90 days).

• Document moderate‑to‑severe HS diagnosis, prior antibiotic use and duration (≥90 days), and prior biologic exposure if applicable.
• If prior biologic was used, include agent and reason for discontinuation.

Submit PA evidence aligning indication with FDA labeling or pivotal trials

Confirm the requested indication matches FDA‑approved or strong trial evidence (examples: polyarticular JIA age ≥4 with weight‑based dosing; pediatric Crohn's disease age ≥6 with trial induction/maintenance dosing). Include prior treatment history, weight for pediatric dosing, and relevant disease activity scores to support the PA.

• For JIA, include weight and ACR Pedi responses or trial evidence alignment.
• For pediatric Crohn's, document induction dosing used and PCDAI or clinical response per trial definitions.

Align PA with labeled indications and supporting evidence

Prior authorization decisions should reflect FDA approvals and guideline recommendations for indications such as RA, UC, and non‑infectious uveitis; include indication‑specific trial evidence and the labeled dosing regimen in the PA submission.

• For UC, include induction regimen (160 mg then 80 mg) and plan for maintenance dosing (40 mg e.o.w.) and note that continuation requires evidence of clinical remission by 8 weeks.
• For RA, document prior DMARD use or positive biomarkers per policy criteria.

Include clinical justification and assay details for drug/antibody testing

Requests to perform serum adalimumab or anti‑adalimumab antibody testing must include a clinical rationale because universal cut‑offs are not established and assay variability limits interpretation; provide test methodology when available to support use of results.

• Report the specific assay used and explain how results will affect management (e.g., dose escalation vs switch).
• Note that low‑titer antibodies may be transient and high‑titer antibodies with undetectable drug levels are more likely to be clinically meaningful.

Provide clinical justification when PA seeks TDM‑based dosing changes

When proposing dose changes or therapy decisions based on therapeutic drug monitoring (TDM), prior authorization may require supporting clinical justification because RCT evidence (e.g., SERENE CD and adult trials) does not consistently show proactive TDM improves outcomes in adults.

• For proactive TDM‑based changes in adults, document failure of clinical‑adjustment strategies or provide rationale why TDM is preferred.
• For pediatric cases where RCT evidence exists (e.g., select pediatric CD data), include trial alignment and target troughs if used.

Do not rely on appendix material alone for PA requests

No prior authorization criteria or billing code changes are specified in the appendix/reference excerpts; do not submit PA requests solely based on appendix material without citation to the main criteria sections.

• Appendix and reference chunks contain administrative or background material only and do not establish PA criteria.

Administrative/reference content — not PA criteria

This portion of the document contains references and administrative material only and does not set prior authorization criteria; reference policy history (last review date) when submitting documentation if relevant.

• Policy history: Last review 02/20/2024; Effective 03/25/2003; Next review 10/24/2024.

Document required prior trials or intolerance for step therapy

Prior authorization requires documentation of prior trials or intolerance/contraindication to specified conventional therapies (e.g., methotrexate, NSAIDs, antibiotics, corticosteroids, other conventional DMARDs) as applicable to the indication per policy.

• RA: inadequate response to at least 3 months of methotrexate (titrated to ≥15 mg/week) or intolerance.
• AS/axSpA: inadequate response to at least two NSAIDs.
• HS: inadequate response to oral antibiotic regimen for ≥90 days.

Indicate biosimilar product and label exceptions on PA; follow payer substitution preferences

Biosimilars are available and carry largely the same labeled indications as Humira, but they are not automatically interchangeable; indicate biosimilar selection and note any labeling exceptions (e.g., some biosimilars omit pediatric HS or UC) on the PA to reflect step or substitution preferences.

• Abrilada, Amjevita, Cyltezo and others are biosimilars with some pediatric/indication omissions — include product‑specific labeling considerations in the PA.
• Confirm payer formulary preferences for biosimilar step or substitution before initiating therapy.

Document NSAID failure and disease activity for AS/axSpA PA

For ankylosing spondylitis, prior authorization should document inadequate response to NSAIDs (at least two trials) or intolerance; include BASDAI/ASDAS scores or other objective measures when available to support disease activity.

• Trials in nr‑axSpA used BASDAI ≥4 as an inclusion criterion; include relevant disease activity indices where available.
• Record prior NSAID agents and durations to show inadequate response.

Document ≥2 NSAID trials before TNFi for axial SpA unless contraindicated

Guidance sources recommend a trial of at least two NSAIDs before initiating a TNF inhibitor for active axial spondyloarthritis; document the agents and durations when requesting authorization for adalimumab.

• If NSAID trial was not feasible, document intolerance or contraindication to support authorization.
• Include dates and outcomes of NSAID trials in the request.

If adalimumab used for HS, explain why infliximab is not chosen and document prior therapies

Clinical guidance notes infliximab as a commonly preferred agent for severe/refractory HS; when requesting adalimumab, provide rationale if infliximab is not selected or is not feasible and document prior therapies and HS severity consistent with trial populations.

• If infliximab was not used due to IV access, contraindication, or patient factors, state this in the PA.
• Include PIONEER trial severity measures and prior treatment history supporting adalimumab use.

Document prior NSAID/DMARD therapy and concomitant use rationale for PsA PA

For psoriatic arthritis, document prior use or failure of NSAIDs and/or conventional DMARDs (e.g., methotrexate) when applicable; note whether adalimumab will be used with methotrexate or as monotherapy per trial evidence.

• Trials commonly included patients with inadequate response to NSAIDs; include joint counts and prior DMARD history.
• If using concomitant methotrexate, document dose and rationale.

Document DMARD trial (methotrexate) and disease activity for RA PA

For rheumatoid arthritis, document trial and inadequate response to conventional DMARD monotherapy (methotrexate preferred) prior to requesting a TNF inhibitor, unless there is intolerance or contraindication; include disease activity measures supporting need for biologic therapy.

• Provide methotrexate dose/duration (≥15 mg/week) or documentation of intolerance.
• Include objective measures (tender/swollen joint counts, CRP/ESR) as available.

Reflect recommended biologic sequencing for ocular Behçet and JIA‑associated uveitis in PA

Consensus guidance places adalimumab as a first‑line biologic for ocular Behçet disease and as a second‑line option for juvenile arthritis–associated uveitis after failure of antimetabolite or calcineurin inhibitor therapy; reflect this sequencing and prior therapy in PA submissions.

• For Behçet ocular disease, document prior therapies and specialist recommendation.
• For JIA‑associated uveitis, document failure of antimetabolites or calcineurin inhibitors before adalimumab.

Prefer clinical‑adjustment/reactive TDM; document failures before proactive TDM requests

Support routine clinical‑adjustment and reactive TDM approaches: document clinical signs/symptoms and biomarker results before requesting proactive TDM; reactive TDM (testing in response to loss of response) is supported as standard care in adults.

• If requesting proactive TDM, provide a rationale and evidence that reactive or clinical‑adjustment strategies have failed.
• Reactive TDM requests should include current disease activity measures and reasons for testing.

Appendix excerpts do not create new step therapy rules

No step therapy requirements are described in the appendix/reference excerpts; do not cite appendix sections as establishing step therapy obligations when submitting PA.

• Appendix excerpts are informational and not a source of PA step mandates.

Do not substitute references for the policy's explicit PA criteria

References and guideline citations in the excerpt do not themselves change PA requirements; rely on the policy's explicit criteria when preparing authorization requests.

• Cite the policy criteria and relevant trial or guideline evidence in the PA rather than external references alone.

Obtain documented negative TB test within 6 months and follow positive‑test workup

Document a negative TB screening test (PPD/TST or IGRA) within 6 months prior to initiating adalimumab for biologic‑ or targeted‑synthetic‑naive persons; if TB screening is positive, obtain further testing (e.g., chest x‑ray) to exclude active disease and treat latent TB before starting therapy. Ensure the prescriber specialty is one of those listed in the policy.

• Do not administer adalimumab to members with active TB.
• When TST is used, an induration ≥5 mm is considered positive per product labeling.

Document indication and dosing regimen aligned to label and patient age/weight

Document the indication and dosing consistent with labeled regimens (e.g., Crohn's induction 160 mg then 80 mg; UC induction 160 mg then 80 mg and maintenance 40 mg e.o.w.; HS dosing: induction 160 mg then 80 mg then 40 mg weekly or 80 mg e.o.w.). Include patient age and weight for pediatric dosing.

• Pediatric weight‑based dosing must be documented (e.g., JIA: 15 kg–<30 kg = 20 mg e.o.w.; ≥30 kg = 40 mg e.o.w.).
• For UC, continuation limited to patients with clinical remission by 8 weeks.

Include pre‑initiation infectious disease screening and monitoring plans

Before initiation, document TB risk assessment and testing results (TST or IGRA and chest radiograph if indicated), hepatitis B carrier status, and plan for monitoring signs of serious infection or reactivation during therapy.

• Screen for HBV carrier status and document management plan if positive.
• Include chest x‑ray when TB screening is positive to exclude active disease.

Provide disease activity indices and prior therapy response documentation

Include diagnosis‑specific activity indices and prior treatment responses in the PA documentation (examples: BASDAI/ASDAS for axial SpA; CDAI/PCDAI and induction response for Crohn's; PASI/PGA for psoriasis).

• For axSpA, include BASDAI or ASDAS and record inadequate response to NSAIDs.
• For Crohn's, document response to induction dosing (e.g., CDAI decrease ≥70) when seeking maintenance approval.

Include HS trial‑consistent severity and prior‑therapy details for PA

For hidradenitis suppurativa PA, include documentation of prior treatments tried, duration, and HS severity consistent with PIONEER trial populations (moderate‑to‑severe HS), and indicate whether weekly or e.o.w. dosing is planned per label.

• Document prior antibiotic regimens and durations (e.g., ≥90 days) and HS‑PGA or abscess/nodule counts if available.
• Note whether infliximab was considered and reasons for selecting adalimumab instead.

Submit trial‑aligned clinical documentation for FDA‑supported indications

For indications supported by pivotal RCTs (e.g., JIA, pediatric Crohn's, plaque psoriasis, PsA), include documentation of diagnosis, prior therapies tried/failed, disease severity measures used in trials (e.g., ACR Pedi, PCDAI, PASI), and patient weight for pediatric dosing.

• Attach trial‑aligned outcome measures (ACR Pedi scores, PCDAI, PASI) to support medical necessity.
• For pediatric cases, explicitly state weight and match dosing to label.

Provide objective inflammatory evidence and drug/antibody data when documenting UC loss of response

When assessing loss of response in ulcerative colitis, include objective evidence of inflammation (endoscopy or surrogates such as CRP or fecal calprotectin), exclude enteric infections, and report serum drug and anti‑drug antibody levels when available to guide management decisions.

• Document endoscopic findings or CRP/fecal calprotectin values and stool studies to exclude infection.
• If sending drug/antibody levels, include assay used and interpretation relative to clinical picture.

Attach objective inflammation data and TDM results when used to justify therapy changes

Document objective signs of inflammation (endoscopy or CRP/fecal calprotectin) and clinical evaluation when claiming inadequate response; include serum trough concentration and anti‑drug antibody results when available to support management decisions.

• State the assay used for drug/antibody testing and explain how results will change therapy.
• If no objective inflammation is present, provide rationale for continued therapy or alternative management.

Submit full TDM and clinical dataset when requesting dose changes based on levels

When using TDM results to guide dosing or switching, provide documentation of measured trough drug concentrations, anti‑drug antibody status, clinical disease activity indices, CRP, and endoscopic findings (or rationale for absence) to support the requested change.

• Because thresholds vary by assay, report the numeric trough value, assay method, and clinical correlation.
• Include prior dosing history and timing of trough sample relative to dosing.

Follow the policy's documented PA submission requirements rather than appendix text

Appendix/reference excerpts do not provide specific documentation submission requirements; rely on the policy's documentation section for PA content rather than appendix text.

• If uncertain, reference the policy's 'Required clinical documentation' and 'Pre‑initiation infectious disease screening' sections when preparing PA.

Reference policy history/review dates when relevant to documentation

Include policy review dates or policy history references when relevant to the PA submission (policy last reviewed 02/20/2024); administrative/history material alone does not establish medical necessity.

• Cite last review date if submitting new evidence or when contesting a prior denial.

Do not start therapy with active TB; follow positive TB screening workup

Do not administer adalimumab to patients with active tuberculosis. If TB screening is positive, obtain further testing (e.g., chest x‑ray) to exclude active disease and initiate latent TB treatment prior to starting adalimumab.

• A positive TB screening requires chest radiograph to exclude active pulmonary TB before initiating therapy.
• Per labeling, treat latent TB infection before starting adalimumab.

Concurrent biologic/targeted synthetic therapy for same indication is investigational

Concomitant use of adalimumab with another biologic or targeted synthetic therapy for the same indication is considered experimental/investigational and may be denied; do not request concurrent biologic combinations for the same condition without strong evidence.

• Examples include combining adalimumab with abatacept, anakinra, etanercept, infliximab, tocilizumab, or tofacitinib for the same indication.
• If combination therapy is clinically justified (e.g., complex cases), include robust supporting evidence and rationale in the PA.

Anser ADA, InformTx TDM, and ADALX tests are considered investigational

Claims for Anser ADA, InformTx TDM, or ADALX serum adalimumab/antibody testing in management of adalimumab therapy are considered experimental/investigational and may be denied; provide strong clinical justification and assay details if submitted for consideration.

• Aetna considers Anser ADA, InformTx TDM, and ADALX investigational for managing adalimumab.
• If testing is requested, include rationale for how results will change management and the assay methodology.

Avoid non‑covered ICD‑10 codes; submit PA only for policy‑supported diagnoses

Use of adalimumab for indications coded within infectious/parasitic disease categories (A00‑B99) or other ICD‑10 diagnoses listed as not covered may be denied; ensure the ICD‑10 code submitted matches a policy‑supported indication.

• Examples of not‑covered codes include active infectious and parasitic diseases (A00‑B99) and selected orphan/metabolic disorder codes listed in the policy.
• If treating an off‑label condition, include compelling evidence and rationale in the PA, recognizing denial risk.

Expect denial risk for off‑label uses without guideline or trial support

Prescribing adalimumab outside labeled indications or guideline‑supported uses (off‑label) carries denial risk; include guideline support or high‑quality trial evidence and comprehensive clinical documentation when requesting PA for off‑label but guideline‑supported scenarios.

• Examples with higher denial risk include spondyloarthritis subtypes not listed in Humira labeling.
• Provide detailed rationale and literature support for off‑label requests.

Giant cell arteritis use may be denied—RCT showed no steroid‑sparing benefit

For giant cell arteritis, randomized trial evidence showed no added benefit of adalimumab plus prednisone versus placebo for steroid‑sparing remission at 6 months; absence of demonstrated benefit supports potential denial for this indication.

• Seror et al. RCT (n=70) found no significant difference in remission on reduced prednisone at 6 months between adalimumab and placebo groups.

Hand osteoarthritis indication has high denial risk due to negative RCT

Adalimumab was not superior to placebo for refractory hand osteoarthritis in an RCT and this negative trial supports potential denial for that indication when requested for analgesic‑refractory hand OA.

• Chevalier et al. randomized trial showed no significant benefit of adalimumab over placebo for hand OA pain outcomes.

Limited‑evidence indications (e.g., LP, MPS I/II) carry denial risk

Use of adalimumab for lichen planus or mucopolysaccharidosis I/II is supported only by case reports or very small pilot studies and UpToDate does not list adalimumab as a recommended therapy; such requests may be denied as experimental or insufficient evidence.

• Provide strong specialty documentation and rationale if seeking authorization for these limited‑evidence indications.

UC maintenance requires documented clinical remission by 8 weeks to continue coverage

Continuation of adalimumab for ulcerative colitis should be limited to patients who have demonstrated clinical remission by 8 weeks of therapy; lack of remission by that time may support discontinuation or denial of continued therapy.

• For UC, document clinical remission (Mayo score ≤2 with no subscore >1) by Day 57 to support ongoing maintenance therapy.
• If no remission, include objective evidence and rationale for continued treatment in PA.

Trough level results alone are unlikely to justify coverage without clinical context

A lack of validated universal trough concentration thresholds reliably associated with remission means routine adalimumab level testing alone is unlikely to justify coverage changes; include clinical context and assay details when submitting level‑based claims.

• Studies show overlap and variability in concentrations between responders and nonresponders and no single threshold is universally accepted.
• Provide how the result will alter management and include objective measures of inflammation.

Report assay method and clinical correlation—assay variability raises denial risk

Assay variability and absence of standardized cut‑offs increase the likelihood that drug/antibody test results will be considered investigational or non‑actionable; include assay method and interpretation tied to patient‑specific clinical data when submitting requests.

• Different commercial assays have differing sensitivity; report the assay name and method used.
• High‑titer antibodies with undetectable drug may be more actionable than low/titular transient antibodies.

Proactive TDM in adults may be denied—document prior clinical adjustment or reactive need

Because proactive or reactive TDM has not demonstrated consistent superiority for improving clinical remission in adults, proactive TDM‑based monitoring used solely to justify therapy changes may be denied; document prior clinical‑adjustment attempts or reactive testing needs to support authorization.

• Cite SERENE CD and related trials showing no clear benefit of proactive TDM over clinical adjustment in adults.
• Reactive TDM in response to loss of response is a supported strategy; document that scenario when requesting testing.

Appendix/reference excerpts are not actionable for PA/denial triggers

Not applicable—these appendix/reference chunks do not specify actionable authorization or denial triggers; do not use them as standalone justification for PA decisions.

• Use main policy criteria sections for medical necessity determinations.

Administrative/policy history content — no clinical PA criteria

Administrative and policy history material does not create clinical action requirements; rely on the policy's explicit criteria when preparing authorizations and appeals.

• Policy history available: Last review 02/20/2024; effective date 03/25/2003.